CA1335289C
(fr)
*
|
1987-10-26 |
1995-04-18 |
Fujio Antoku |
Derives piperidinylbenzisoxazole, leur production et leur utilisation pharmaceutique
|
US5116970A
(en)
*
|
1988-02-18 |
1992-05-26 |
New James S |
Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
|
US5001130A
(en)
*
|
1988-02-18 |
1991-03-19 |
Bristol-Myers Company |
Psychotropic heterobicycloalkylpiperazine derivatives
|
GR1000667B
(el)
*
|
1988-03-21 |
1992-09-25 |
Janssen Pharmaceutica Nv |
Μεθοδος παρασκευης 3-πιπεριδινυλο-1,2-βενζισοξαζολων.
|
US5015740A
(en)
*
|
1988-08-05 |
1991-05-14 |
Janssen Pharmaceutica N.V. |
Antipsychotic 3-piperazinylbenzazole derivatives
|
NZ230045A
(en)
*
|
1988-08-05 |
1990-11-27 |
Janssen Pharmaceutica Nv |
3-piperazinylbenzazole derivatives and pharmaceutical compositions
|
US4957916A
(en)
*
|
1988-08-05 |
1990-09-18 |
Janssen Pharmaceutica N.V. |
Antipsychotic 3-piperazinylbenzazole derivatives
|
US5321028A
(en)
*
|
1988-09-02 |
1994-06-14 |
Janssen Pharmaceutica N.V. |
Antihypertensive 3-piperidinyl-indazole derivatives
|
IL90879A0
(en)
*
|
1988-09-02 |
1990-02-09 |
Janssen Pharmaceutica Nv |
3-piperidinyl-indazole derivatives,their preparation and antihypertensive compositions containing them
|
US5196425A
(en)
*
|
1988-09-02 |
1993-03-23 |
Janssen Pharmaceutica N.V. |
Antihypertensive 3-piperidinyl-indazole derivatives
|
CA2000786C
(fr)
*
|
1988-11-07 |
1999-01-26 |
Cornelus G. M. Janssen |
3-piperidinyl-1,2-benzisoxazoles
|
US5158952A
(en)
*
|
1988-11-07 |
1992-10-27 |
Janssen Pharmaceutica N.V. |
3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
|
US5254556A
(en)
*
|
1988-11-07 |
1993-10-19 |
Janssen Pharmaceutica N.V. |
3-piperidinyl-1,2-benzisoxazoles
|
HU207310B
(en)
*
|
1988-12-02 |
1993-03-29 |
Pfizer |
Process for producing aryl-piperidine derivatives
|
FR2641278B1
(fr)
*
|
1989-01-05 |
1991-03-22 |
Lipha |
Piperidines, procedes de preparation et medicaments les contenant
|
US5256659A
(en)
*
|
1989-01-09 |
1993-10-26 |
Janssen Pharmaceutica N.V. |
2-aminopyrimidinone derivatives
|
GB8900382D0
(en)
*
|
1989-01-09 |
1989-03-08 |
Janssen Pharmaceutica Nv |
2-aminopyrimidinone derivatives
|
FR2654104B1
(fr)
*
|
1989-11-07 |
1992-01-03 |
Adir |
Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
|
FR2671350A1
(fr)
*
|
1991-01-08 |
1992-07-10 |
Adir |
Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
|
GB9008850D0
(en)
*
|
1990-04-19 |
1990-06-13 |
Janssen Pharmaceutica Nv |
Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
|
US5075315A
(en)
*
|
1990-05-17 |
1991-12-24 |
Mcneilab, Inc. |
Antipsychotic hexahydro-2H-indeno[1,2-c]pyridine derivatives
|
JP2869512B2
(ja)
*
|
1990-06-01 |
1999-03-10 |
メレルダウファーマスーティカルズ インコーポレイテッド |
(+)―α―(2,3―ジメトキシフェニル)―1―[2―(4―フルオロフェニル)エチル]―4―ピペリジンメタノール
|
US6004980A
(en)
*
|
1990-06-01 |
1999-12-21 |
Merrell Pharmaceuticals, Inc. |
(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
|
US5147881A
(en)
*
|
1990-11-14 |
1992-09-15 |
Pfizer Inc |
4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
|
EP0602242A4
(en)
*
|
1991-08-22 |
1994-06-29 |
Yoshitomi Pharmaceutical |
Benzisoxazole compound and use thereof.
|
ES2096099T3
(es)
*
|
1991-09-25 |
1997-03-01 |
Pfizer |
Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
|
US5532243A
(en)
*
|
1992-02-14 |
1996-07-02 |
The Dupont Merck Pharmaceutical Company |
Antipsychotic nitrogen-containing bicyclic compounds
|
DE4243287A1
(de)
*
|
1992-06-19 |
1993-12-23 |
Basf Ag |
N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
|
PT672043E
(pt)
|
1992-07-13 |
2001-11-30 |
Janssen Pharmaceutica Nv |
Novos derivados de 4-(3-benzofuranil)piperidinilo e 4-(3-benzotienil)piperidinilo e composicoes farmaceuticas que os contem
|
TW376319B
(en)
*
|
1993-04-28 |
1999-12-11 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
|
DE4338396A1
(de)
*
|
1993-11-10 |
1995-05-11 |
Basf Ag |
N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
|
CN1074923C
(zh)
*
|
1993-11-19 |
2001-11-21 |
詹森药业有限公司 |
微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
|
US5688799A
(en)
*
|
1993-11-23 |
1997-11-18 |
Janssen Pharmaceutica N.V. |
9-Hydroxy-pyrido 1,2-a!pyrimidin-4-one ether derivatives
|
ES2074966B1
(es)
*
|
1994-02-11 |
1996-06-16 |
Vita Invest Sa |
Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il)piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a)pirimidin-4-ona.
|
ES2085234B1
(es)
*
|
1994-02-24 |
1997-01-16 |
Vita Invest Sa |
Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
|
CA2144669A1
(fr)
*
|
1994-03-29 |
1995-09-30 |
Kozo Akasaka |
Derives du biphenyle
|
EP0794185A4
(fr)
*
|
1994-11-25 |
1998-03-25 |
Meiji Seika Co |
Compose thiazole bicyclique
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
EP0812318B1
(fr)
|
1995-02-28 |
2006-02-08 |
H. Lundbeck A/S |
Composes 4-aminotetrahydrobenzisoxazole ou -isothiazole
|
TW592729B
(en)
*
|
1995-04-06 |
2004-06-21 |
Janssen Pharmaceutica Nv |
Rate-controlled transdermal administration of risperidone
|
KR960042947A
(ko)
*
|
1995-05-09 |
1996-12-21 |
김주용 |
고집적 반도체 소자 및 그 국부 연결 방법
|
ES2097093B1
(es)
*
|
1995-05-26 |
1998-01-16 |
Ferrer Int |
Nuevos compuestos derivados de 5h-tiazolo (3,2-a) pirimidin-5-ona.
|
US6028083A
(en)
*
|
1997-07-25 |
2000-02-22 |
Hoechst Marion Roussel, Inc. |
Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
|
UA72189C2
(uk)
*
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
ES2141671B1
(es)
*
|
1997-12-26 |
2001-01-01 |
Vita Invest Sa |
Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
|
FR2802101B1
(fr)
*
|
1999-12-10 |
2003-02-28 |
Aventis Pharma Sa |
Association de cymemazine et d'un neuroleptique atypique
|
US6770478B2
(en)
*
|
2000-02-10 |
2004-08-03 |
The Regents Of The University Of California |
Erythrocytic cells and method for preserving cells
|
ATE264329T1
(de)
|
2000-05-05 |
2004-04-15 |
Rpg Life Sciences Ltd |
Verfahren zur herstellung von antipsychotischem 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-
|
US6264987B1
(en)
|
2000-05-19 |
2001-07-24 |
Alkermes Controlled Therapeutics Inc. Ii |
Method for preparing microparticles having a selected polymer molecular weight
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
AU2001284763A1
(en)
*
|
2000-08-08 |
2002-02-18 |
Teva Pharmaceutical Industries Ltd. |
Preparation of risperidone
|
MXPA03001337A
(es)
*
|
2000-08-14 |
2005-06-30 |
Teva Pharma |
Preparacion de risperidona.
|
EP1783118B1
(fr)
*
|
2000-08-14 |
2008-07-16 |
Teva Pharmaceutical Industries Ltd. |
Préparation de rispéridone
|
US6824822B2
(en)
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US20040023951A1
(en)
*
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
DE10129320A1
(de)
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
US6730772B2
(en)
|
2001-06-22 |
2004-05-04 |
Venkatram P. Shastri |
Degradable polymers from derivatized ring-opened epoxides
|
EP2305656B1
(fr)
*
|
2001-08-31 |
2012-10-24 |
Novartis AG |
Isomeres optiques d'un metabolite d'iloperidone
|
HU227118B1
(en)
*
|
2001-11-13 |
2010-07-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
|
ES2364037T3
(es)
*
|
2001-12-10 |
2011-08-23 |
Novartis Ag |
Métodos de tratamiento de psicosis y esquizofrenia basados en polimorfismos del gen del cntf.
|
ES2197801B1
(es)
*
|
2002-03-05 |
2005-03-16 |
Ferrer Internacional,S.A |
Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
|
WO2004009591A1
(fr)
*
|
2002-07-22 |
2004-01-29 |
Aurobindo Pharma Ltd. |
Procede de preparation de risperidone antipsychotique
|
US20050232995A1
(en)
*
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
AU2003250472A1
(en)
*
|
2002-08-23 |
2004-03-11 |
Ranbaxy Laboratories Limited |
Stable aqueous solutions of risperidone and methods for their preparation
|
WO2004020439A2
(fr)
*
|
2002-08-30 |
2004-03-11 |
Sunil Sadanand Nadkarni |
Procede de preparation de risperidone ameliore
|
KR20040025224A
(ko)
*
|
2002-09-18 |
2004-03-24 |
주식회사 대웅 |
2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4H-피리도[1,2-a]피리미딘-3-일)아세트알데히드 및 그 제조방법
|
KR20040034996A
(ko)
*
|
2002-10-18 |
2004-04-29 |
한미약품 주식회사 |
리스페리돈의 개선된 제조방법
|
US6800663B2
(en)
*
|
2002-10-18 |
2004-10-05 |
Alkermes Controlled Therapeutics Inc. Ii, |
Crosslinked hydrogel copolymers
|
EP1560814A1
(fr)
|
2002-11-13 |
2005-08-10 |
Synthon B.V. |
Procede de fabrication de la risperidone et des intermediaires associes
|
DE10259382A1
(de)
*
|
2002-12-18 |
2004-07-01 |
Abbott Gmbh & Co. Kg |
3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
|
WO2004064752A2
(fr)
*
|
2003-01-22 |
2004-08-05 |
Alkermes Controlled Therapeutics, Inc. |
Procede de preparation de microparticules a liberation prolongee
|
WO2004094415A1
(fr)
*
|
2003-04-22 |
2004-11-04 |
Synthon B.V. |
Monochlorhydrates de risperidone
|
JP2006528676A
(ja)
*
|
2003-05-16 |
2006-12-21 |
ファイザー・プロダクツ・インク |
非定形型抗精神病薬と、gaba調節薬及び/又は抗痙攣薬の治療上の組合せ
|
US20050036977A1
(en)
*
|
2003-08-11 |
2005-02-17 |
Dilip Gole |
Taste-masked resinate and preparation thereof
|
AU2004276092A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Jubilant Organosys Ltd. |
Process for the preparation of risperidone
|
GB0322994D0
(en)
*
|
2003-10-01 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
ES2315721T5
(es)
*
|
2003-10-23 |
2012-08-24 |
Otsuka Pharmaceutical Co., Ltd. |
Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
EP1689721B1
(fr)
*
|
2003-11-26 |
2010-07-14 |
Pfizer Products Inc. |
Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
|
EP1737473A4
(fr)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
Combinaisons de lithium et utilisations associees
|
MXPA06013163A
(es)
*
|
2004-05-11 |
2007-02-13 |
Pfizer Prod Inc |
Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
|
MY147767A
(en)
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
US20060004199A1
(en)
*
|
2004-07-01 |
2006-01-05 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
MY142329A
(en)
*
|
2004-08-24 |
2010-11-15 |
Janssen Pharmaceutica Nv |
Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
|
US7744918B2
(en)
*
|
2004-11-22 |
2010-06-29 |
Hisamitsu Pharmaceutical Co., Inc. |
Drug-containing patch
|
EP1863485A2
(fr)
*
|
2005-03-18 |
2007-12-12 |
Abbott Laboratories |
Ligand du recepteur nicotinique neuronal alpha7 et compositions antipsychotiques
|
MX2007013026A
(es)
*
|
2005-04-22 |
2008-01-11 |
Wyeth Corp |
Combinaciones terapeuticas para el tratamiento o prevencion de trastornos psicoticos.
|
KR20080012360A
(ko)
*
|
2005-05-20 |
2008-02-11 |
얀센 파마슈티카 엔.브이. |
설파미드 유도체의 제조 방법
|
WO2006129160A2
(fr)
*
|
2005-06-01 |
2006-12-07 |
Aurobindo Pharma Limited |
Solutions aqueuses stables d'un agent antipsychotique
|
EP1933814A2
(fr)
*
|
2005-09-15 |
2008-06-25 |
Elan Pharma International Limited |
Formulations aripiprazoliques nanoparticulaires
|
US20070134310A1
(en)
*
|
2005-09-23 |
2007-06-14 |
Nedberge Diane E |
Transdermal risperidone delivery system
|
US8852638B2
(en)
|
2005-09-30 |
2014-10-07 |
Durect Corporation |
Sustained release small molecule drug formulation
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8937096B2
(en)
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US8716231B2
(en)
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US8492431B2
(en)
*
|
2005-12-19 |
2013-07-23 |
Janssen Pharmaceutica, N.V. |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
|
US20070155824A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
|
US20070191451A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
|
US20070191460A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
|
GB0603087D0
(en)
*
|
2006-02-15 |
2006-03-29 |
Glaxo Group Ltd |
Novel use
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
US20070191450A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
|
JP4922657B2
(ja)
*
|
2006-05-09 |
2012-04-25 |
高田製薬株式会社 |
リスペリドン経口用液剤
|
TW200812573A
(en)
*
|
2006-05-19 |
2008-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy for the treatment of epilepsy and related disorders
|
AU2007253684A1
(en)
*
|
2006-05-22 |
2007-11-29 |
Vanda Pharmaceuticals, Inc. |
Treatment for depressive disorders
|
EP2041304B1
(fr)
*
|
2006-06-12 |
2011-09-07 |
Hadasit Medical Research Services & Development Limited |
Génotypes rgs2 associés aux symptômes extrapyramidaux induits par un médicament antipsychotique
|
US20080004260A1
(en)
*
|
2006-06-29 |
2008-01-03 |
Transcept Pharmaceuticals, Inc. |
Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
|
JP2009512627A
(ja)
*
|
2006-08-14 |
2009-03-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
9−ヒドロキシリスペリドン(パリペリドン)の合成方法
|
WO2008047340A1
(fr)
*
|
2006-10-19 |
2008-04-24 |
Mor Research Applications Ltd. |
Thérapies combinées d'antipsychotiques et de tétracyclines dans le traitement de troubles psychiatriques
|
JP2010510314A
(ja)
|
2006-11-22 |
2010-04-02 |
シーサイド セラピューティクス,エルエルシー |
精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
|
CN101600716A
(zh)
*
|
2007-01-08 |
2009-12-09 |
阿特维斯集团公司 |
用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
|
CN101245065B
(zh)
*
|
2007-02-14 |
2010-05-19 |
江苏恩华药业股份有限公司 |
制备苯并异噁唑衍生物的方法及其中间体
|
JP4941977B2
(ja)
*
|
2007-04-11 |
2012-05-30 |
大蔵製薬株式会社 |
ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
|
CA2687979C
(fr)
*
|
2007-05-25 |
2017-07-04 |
Tolmar Therapeutics, Inc. |
Formulations d'administration prolongee de composes de risperidone
|
UA97286C2
(ru)
*
|
2007-07-31 |
2012-01-25 |
Оцука Фармасьютикал Ко., Лтд. |
Способ изготовления суспензии арипипразола и лиофилизированного состава
|
WO2009056990A2
(fr)
*
|
2007-08-21 |
2009-05-07 |
Actavis Group Ptc Ehf |
Polymorphes de la palipéridone
|
ATE530170T1
(de)
*
|
2007-08-21 |
2011-11-15 |
Teva Pharma |
Paliperidonformulierung mit verzögerter freisetzung
|
US7776866B2
(en)
*
|
2007-09-15 |
2010-08-17 |
Protia, Llc |
Deuterium-enriched risperidone
|
ES2436658T3
(es)
|
2007-12-10 |
2014-01-03 |
Synthon B.V. |
Síntesis de paliperidona
|
ES2868353T3
(es)
*
|
2007-12-19 |
2021-10-21 |
Janssen Pharmaceutica Nv |
Régimen de dosificación asociado a ésteres de paliperidona inyectables de larga acción
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
EP2280967A2
(fr)
*
|
2008-03-27 |
2011-02-09 |
Actavis Group PTC EHF |
Palipéridone de haute pureté ou sel pharmaceutiquement acceptable de celle-ci sensiblement exempte d impureté céto
|
WO2009128058A1
(fr)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Produits psycho-pharmaceutiques
|
WO2010004578A2
(fr)
|
2008-06-16 |
2010-01-14 |
Msn Laboratories Limited |
Nouveaux procédés améliorés de préparation de la palipéridone
|
US8809385B2
(en)
|
2008-06-23 |
2014-08-19 |
Janssen Pharmaceutica Nv |
Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
|
WO2009156889A1
(fr)
*
|
2008-06-25 |
2009-12-30 |
Pfizer Inc. |
Composés diaryle et leurs utilisations
|
EP2138488A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Dérivés de 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-ones comme inhibiteurs de GSK3-beta utiles pour le traitement de maladies neurodégénératives
|
EP2138493A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Dérivés substitués de pyrimidone
|
EP2138485A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Dérivés substitués de N-oxyde pyrazine
|
EP2138492A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Dérivés substitués de pyrimidin-4-one
|
EP2138498A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Dérivés tricycliques substitués contre les maladies neurodégénératives
|
EP2138494A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Dérivés substitués d'alkyl pyrimidin-4-one
|
EP2138495A1
(fr)
*
|
2008-06-26 |
2009-12-30 |
sanofi-aventis |
Dérivés substitués de pyrimido[2,1-a]isoquinolin-4-one
|
WO2010003703A2
(fr)
|
2008-07-11 |
2010-01-14 |
Synthon B.V. |
Palipéridone cétone
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
EP2199293A1
(fr)
|
2008-12-22 |
2010-06-23 |
Chemo Ibérica, S.A. |
Procédé à étape unique pour la préparation de palipéridone en son sel d'oxalate
|
US20100298397A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Singh Nikhilesh N |
Method of treatment of obsessive compulsive disorder with ondansetron
|
WO2010136895A1
(fr)
|
2009-05-28 |
2010-12-02 |
Actavis Group Ptc Ehf |
Formes à l'état solide de sels de palipéridone et leur procédé de préparation
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
ATE544766T1
(de)
|
2009-07-13 |
2012-02-15 |
Krka |
Verfahren zur synthese von paliperidon
|
EP2475663A2
(fr)
|
2009-09-10 |
2012-07-18 |
Actavis Group Ptc Ehf |
Palipéridone ou sel pharmaceutiquement acceptable de celui-ci sensiblement exempt d'impuretés
|
AU2010339689B2
(en)
|
2010-01-07 |
2015-02-19 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
WO2011114213A1
(fr)
|
2010-03-15 |
2011-09-22 |
Inventia Healthcare Private Limited |
Composition pharmaceutique stabilisée, à libération prolongée, comprenant un antipsychotique atypique
|
GB2513060B
(en)
|
2010-06-08 |
2015-01-07 |
Rb Pharmaceuticals Ltd |
Microparticle buprenorphine suspension
|
US9272044B2
(en)
|
2010-06-08 |
2016-03-01 |
Indivior Uk Limited |
Injectable flowable composition buprenorphine
|
US20130190299A1
(en)
|
2010-06-30 |
2013-07-25 |
Victoria Link Ltd. |
Methods and compositions for treatment of multiple sclerosis
|
US8778960B2
(en)
|
2010-08-23 |
2014-07-15 |
Alkermes Pharma Ireland Limited |
Methods for treating antipsychotic-induced weight gain
|
WO2012035554A1
(fr)
|
2010-09-14 |
2012-03-22 |
Megafine Pharma (P) Ltd. |
Procédé amélioré de préparation de palipéridone très pure
|
EP2640391B1
(fr)
|
2010-11-15 |
2015-11-11 |
Agenebio, Inc. |
Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
|
US9040695B2
(en)
|
2011-04-26 |
2015-05-26 |
Torrent Pharmaceuticals Limited |
Acid addition salts of risperidone and pharmaceutical compositions thereof
|
WO2013095314A1
(fr)
|
2011-12-19 |
2013-06-27 |
Mahmut Bilgic |
Formulations pharmaceutiques comprenant de la rispéridone
|
WO2013100876A1
(fr)
|
2011-12-27 |
2013-07-04 |
Mahmut Bilgic |
Formulations de rispéridone
|
JP6374387B2
(ja)
*
|
2012-08-21 |
2018-08-15 |
ヤンセン ファーマシューティカ エヌ.ベー. |
リスペリドンハプテンへの抗体及びその使用
|
TR201816416T4
(tr)
|
2012-08-21 |
2018-11-21 |
Janssen Pharmaceutica Nv |
Risperidona yönelik antikorlar ve bunların kullanımı.
|
CN104755479B
(zh)
*
|
2012-08-21 |
2016-11-09 |
詹森药业有限公司 |
利培酮和帕潘立酮的半抗原
|
JP2015529199A
(ja)
|
2012-08-21 |
2015-10-05 |
オルソ−クリニカル ダイアグノスティクス,インコーポレイティド |
パリペリドンハプテンに対する抗体及びその使用
|
CA2882490A1
(fr)
|
2012-08-21 |
2014-02-27 |
Ortho-Clinical Diagnostics, Inc. |
Anticorps diriges contre la paliperidone et leur utilisation
|
CA2885941A1
(fr)
*
|
2012-09-28 |
2014-04-03 |
Delpor, Inc. |
Dispositif et procedes de liberation prolongee de medications antipsychotiques
|
CA2891122C
(fr)
|
2012-11-14 |
2021-07-20 |
The Johns Hopkins University |
Methodes et compositions pour le traitement de la schizophrenie
|
WO2015095783A1
(fr)
|
2013-12-20 |
2015-06-25 |
Agenebio, Inc. |
Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
|
GB201404139D0
(en)
|
2014-03-10 |
2014-04-23 |
Rb Pharmaceuticals Ltd |
Sustained release buprenorphine solution formulations
|
AU2015341490C1
(en)
|
2014-11-07 |
2021-03-11 |
Indivior Uk Limited |
Buprenorphine dosing regimens
|
JP6987384B2
(ja)
|
2015-06-19 |
2021-12-22 |
エージンバイオ, インコーポレイテッド |
ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
|
CA3008809A1
(fr)
|
2015-12-17 |
2017-06-22 |
Janssen Pharmaceutica Nv |
Anticorps anti-risperidone et leur utilisation
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US10646484B2
(en)
|
2017-06-16 |
2020-05-12 |
Indivior Uk Limited |
Methods to treat opioid use disorder
|
BR112020026062B1
(pt)
|
2018-06-19 |
2023-04-04 |
Agenebio, Inc |
Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
|
WO2024039886A1
(fr)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
|